Overview

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals